80 related articles for article (PubMed ID: 8986422)
1. Transgenic models for proliferative and hyperfunctional thyroid diseases.
Ledent C; Coppée F; Dumont JE; Vassart G; Parmentier M
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 3():43-6. PubMed ID: 8986422
[TBL] [Abstract][Full Text] [Related]
2. [Transgenic mouse models. Their interest in thyroid tumors].
Ledent C; Franc B; Parmentier M
Arch Anat Cytol Pathol; 1998; 46(1-2):31-7. PubMed ID: 9754358
[TBL] [Abstract][Full Text] [Related]
3. [Transgenic models of human thyroid pathologies: hyperfunctional adenoma, anaplastic cancer, differentiated cancer, hypothyroidism].
Ledent C
Bull Mem Acad R Med Belg; 1996; 151(2):195-201. PubMed ID: 9004925
[TBL] [Abstract][Full Text] [Related]
4. Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene.
Coppée F; Gérard AC; Denef JF; Ledent C; Vassart G; Dumont JE; Parmentier M
Oncogene; 1996 Oct; 13(7):1471-82. PubMed ID: 8875985
[TBL] [Abstract][Full Text] [Related]
5. Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene.
Ledent C; Marcotte A; Dumont JE; Vassart G; Parmentier M
Oncogene; 1995 May; 10(9):1789-97. PubMed ID: 7753555
[TBL] [Abstract][Full Text] [Related]
6. Production of transgenic mice expressing the Ki-ras oncogene under the control of a thyroglobulin promoter.
Santelli G; de Franciscis V; Portella G; Chiappetta G; D'Alessio A; Califano D; Rosati R; Mineo A; Monaco C; Manzo G
Cancer Res; 1993 Nov; 53(22):5523-7. PubMed ID: 8221693
[TBL] [Abstract][Full Text] [Related]
7. Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter.
Rochefort P; Caillou B; Michiels FM; Ledent C; Talbot M; Schlumberger M; Lavelle F; Monier R; Feunteun J
Oncogene; 1996 Jan; 12(1):111-8. PubMed ID: 8552381
[TBL] [Abstract][Full Text] [Related]
8. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism.
Paschke R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020
[TBL] [Abstract][Full Text] [Related]
9. Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization.
Chiappetta G; Fabien N; Picone A; Califano D; Monaco C; de Franciscis V; Vecchio G; Santelli G
Oncol Res; 1996; 8(2):85-93. PubMed ID: 8859779
[TBL] [Abstract][Full Text] [Related]
10. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium.
Russell JP; Powell DJ; Cunnane M; Greco A; Portella G; Santoro M; Fusco A; Rothstein JL
Oncogene; 2000 Nov; 19(50):5729-35. PubMed ID: 11126359
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profile in thyroid of transgenic mice overexpressing the adenosine receptor 2a.
Goffard JC; Jin L; Mircescu H; Van Hummelen P; Ledent C; Dumont JE; Corvilain B
Mol Endocrinol; 2004 Jan; 18(1):194-213. PubMed ID: 14563936
[TBL] [Abstract][Full Text] [Related]
12. A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas.
Takeda T; Yamazaki M; Minemura K; Imai Y; Inaba H; Suzuki S; Miyamoto T; Ichikawa K; Kakizawa T; Mori J; DeGroot LJ; Hashizume K
Cancer Gene Ther; 2002 Oct; 9(10):864-74. PubMed ID: 12224028
[TBL] [Abstract][Full Text] [Related]
13. Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis.
van Staveren WC; Solís DW; Delys L; Venet D; Cappello M; Andry G; Dumont JE; Libert F; Detours V; Maenhaut C
Proc Natl Acad Sci U S A; 2006 Jan; 103(2):413-8. PubMed ID: 16381821
[TBL] [Abstract][Full Text] [Related]
14. Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice.
Zeiger MA; Saji M; Gusev Y; Westra WH; Takiyama Y; Dooley WC; Kohn LD; Levine MA
Endocrinology; 1997 Aug; 138(8):3133-40. PubMed ID: 9231760
[TBL] [Abstract][Full Text] [Related]
15. Constitutively activating mutations of the thyrotropin receptor and thyroid disease.
Führer D; Holzapfel HP; Wonerow P; Paschke R
Eur J Med Res; 1996 Jul; 1(10):460-4. PubMed ID: 9438142
[TBL] [Abstract][Full Text] [Related]
16. Model of the athymic nude mouse for the study of benign goiter disease.
Gerber H; Wagner HE; Bürgi U; Peter HJ
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 3():56-9. PubMed ID: 8986427
[TBL] [Abstract][Full Text] [Related]
17. Activation of the cAMP cascade in thyroid autonomy.
Paschke R
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 4():S4-5. PubMed ID: 9867187
[No Abstract] [Full Text] [Related]
18. Enhanced functional activity in thyroid adenomas in vitro.
Poertl S; Kirner J; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():39-40. PubMed ID: 8980999
[TBL] [Abstract][Full Text] [Related]
19. Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma.
Johnston D; Hatzis D; Sunday ME
Oncogene; 1998 Jan; 16(2):167-77. PubMed ID: 9464534
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions.
Letsas KP; Frangou-Lazaridis M; Skyrlas A; Tsatsoulis A; Malamou-Mitsi V
Pathol Int; 2005 Nov; 55(11):694-702. PubMed ID: 16271081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
